For instance, initial studies with R26-A3B in an EGFR-driven lung cancer model indicate that A3B is capable of fueling tumor evolution and contributing to drug resistance (even in the absence of inflicting overt APOBEC3 signature mutations).58 The gene discussed is EGFR; the disease is lung cancer.